Many tumour types are difficult to cure, especially metastatic disease. Therapy using radiopharmaceuticals could then be useful, due to the possibility to reach also tumour cells spread in the body. New knowledge regarding tumour biology, pathology and molecular biology demonstrate more tumour specific features/biomarkers that can be used for development of more specific radiopharmaceuticals and treatment strategies.
Our aim is to study the possibilities to develop, optimise and apply new radiopharmaceuticals for therapy, and to optimise treatment protocols. Some of the specific aims are:
1) to optimise treatment with radiolabelled hormone analogues for hormone receptor-expressing tumours,
2) to optimise radioiodine therapy of highly differentiated thyroid tumours e.g. regarding the stunning phenomenon
3) to define possible biomarkers for radiotoxicity in tumour and normal tissues
4) to optimise radionuclide therapy by using enhanced knowledge based on basal molecular studies of radiobiological effects on tumour tissue and critical normal tissues.
5) to enhance the knowledge on radiation dosimetry and tolerance doses for radionuclide therapy in critical normal tissues
Much research is done using the radiolabelled somatostatin analogue 177Lu-octreotate for therapy of neuroendocrine tumours expressing somatostatin receptors. We try to increase the radiobiological effects on tumour tissue by using optimal fractionation schedules, increasing the receptor expression, reducing saturation of receptors, combination with other agents (radiosenstizing). We try to reduce the side effects on critical normal tissues, e.g by reducing kidney uptake and kidney toxicity. We also try to find biomarkers for radiobiological effects (toxicity) on tumour and normal tissues.
We perform studies on cell culture, mice and rats and patients. Pharmacokinetic and dosimetric studies are performed in tumour-bearing animals and man. Studies on toxicity and biological effects (animals) utilizes e.g imaging techniques (scintigraphy, MRI), histopathology and gene expression analysis.
To read more about us please visit our web site: www.radfys.gu.se/FA-lab.
We are part of Sahlgrenska Translational Neuroendocrine Cancer Group (SATNEC). For more information of SATNEC, please visit: www.radfys.gu.se/satnec.